Pneumococcal polysaccharide vaccine: cost–effectiveness recommendations in adults

References

• Felson DS, Musher DM. Pneumococcal polysaccharide vaccine. In: Vaccines, fourth edition. Plotkin SA, Orenstein WA (Eds), Saunders, PA, USA 529–588 (2004).
   Google Scholar
• Advisory Committee on Immunization Practices. Prevention of pneumococcal disease: Recommendations of the Advisory Committee on Immunization Practices. MMWR 46, 1–24 (1997).
   PubMedGoogle Scholar
• Task Force on Community Prevention Service. Recommendations regarding interventions to improve vaccination coverage in children, adolescents and adults. Am. J. Prev. Med. 18(Suppl.), 92–140 (2000).
   PubMed Web of Science ®Google Scholar
• National Centers for Disease Control and Prevention (CDC). Defining the public health impact of drug-resistant Streptococus pneumoniae: report of a working group. MMWR 45, 1–20 (1996).
   PubMedGoogle Scholar
• Doern GV, Brueggemann AB, Huynh H, Wingert E. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997–98. Emerg. Infect. Dis. 5, 757–765 (1999).
   PubMed Web of Science ®Google Scholar
• Mangtani P, Cutts F, Hall AJ. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries. Lancet Infect. Dis. 2, 71–78 (2003).
   Web of Science ®Google Scholar
• Ortqvist A. Pneumococcal vaccination: current and future issues. Eur. Respir. J. 18, 184–195 (2001).
   PubMed Web of Science ®Google Scholar
• Gable CB, Botteman M, Savage G, Joy K. The cost–effectiveness of pneumococcal vaccination stratregies. Pharmacoeconomics 12, 161–174 (1997).
   PubMed Web of Science ®Google Scholar
• Beutels P, Postma MJ. Economic evaluations of adult pneumococcal vaccination strategies. Expert Rev. Pharmacoeconomics Outcomes Res. 1, 47–58 (2001).
   PubMedGoogle Scholar
• Plans P. Cost–effectiveness of 23-valent antipneumococcal vaccination in Catalonia (Spain). Gac. Sanit. 16, 392–400 (2002).
   PubMedGoogle Scholar
• Plans Rubió P, Garrido Morales P, Salleras Sanmartí Ll. Coste-efectividad de la vacunación neumocócica en Cataluña. Rev. Esp. Salud Pública 69, 409–417 (1995).
   PubMedGoogle Scholar
• Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG. Cost–effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race. Ann. Intern. Med. 138, 960–968 (2003).
   PubMed Web of Science ®Google Scholar
• Singletton JA, Greby SM, Wooter KG, Walker FJ, Strikas R. Influenza, pneumonia, and tetanus toxioid vaccination of adults – United States, 19937. MMWR CDC Survill. Summ. C49, 39–62 (2000).
   PubMedGoogle Scholar
• CDC. Influenza and pneumococcal vaccination levels among persons aged ≥ 65 years – United States, 1999. MMWR 50, 532–537 (2001).
   PubMedGoogle Scholar
• Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 12(238), 2613–2616 (1977).
   PubMedGoogle Scholar
• Riley ID, Tarr PI, Andrews M et al. Immunisation with a polyvalent pneumococcal vaccine. Reduction of adult respiratory mortality in a New Guinea Highlands community. Lancet 1, 1338–1341 (1977).
   PubMed Web of Science ®Google Scholar
• Simberkoff MS, Cross AP, Al-Ibrahim M et al. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration Co-operative Study. N. Engl. J. Med. 315, 1318–1327 (1986).
   PubMed Web of Science ®Google Scholar
• French N, Nakiyingi J, Carpenter LM et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo-controlled trial. Lancet 355, 2106–2111 (2000).
   PubMed Web of Science ®Google Scholar
• Gaillat J, Zmirou D, Mallaret MR et al. Clinical trial of an antipneumocccal vaccine in elderly subjects living in institutions. Rev. Epidemiol. Sante Publique 33, 437–444 (1985).
   PubMed Web of Science ®Google Scholar
• Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 136, 361–365 (1987).
   PubMed Web of Science ®Google Scholar
• Davis AL, Aranda CP, Schiffman G, Christianson LC. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. A pilot study. Chest 92, 204–212 (1987).
   PubMed Web of Science ®Google Scholar
• Ortqvist A, Hedlund J, Burman LA et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet 351, 399–403 (1998).
   PubMed Web of Science ®Google Scholar
• Honkanen PO, Keistinen T, Miettinen L et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 17, 2493–2500 (1999).
   PubMed Web of Science ®Google Scholar
• Austrian R. Survillance of Pneumocccal Infection for Field Trials of Polyvalent Pneumococcal Vaccines. National Institute of Allergy and Infectious Diseases, MD, USA DVA-VDP 12–84 (1980).
   Google Scholar
• Koivula I, Sten M, Leinonen M, Makela PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am. J. Med. 103, 281–290 (1997).
   Google Scholar
• Sims RV, Steimann WC, McConville JK, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann. Intern. Med. 108, 653–657 (1988).
   PubMed Web of Science ®Google Scholar
• Butler JC, Breiman RF, Campbell JF et al. Pneumococcal polysaccharide vaccine efficacy. JAMA 270, 1826–1831 (1993).
   PubMed Web of Science ®Google Scholar
• Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide pneumonia. N. Engl. J. Med. 325, 1453–1460 (1991).
   PubMed Web of Science ®Google Scholar
• Dworkin MS, Ward JW, Hanson DL, Jones JL, Kaplan JE. Adult and adolescent Spectrum of HIV Disease Project. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors and impact of vaccination. Clin. Infect. Dis. 32, 794–800 (2001).
   PubMed Web of Science ®Google Scholar
• Farr BM, Johnston BL, Cobb DK et al. Preventing pneumococcal bacteremia in patients at risk. Results of a matched case-control study. Arch. Intern. Med. 155, 2336–2340 (1995).
   PubMed Web of Science ®Google Scholar
• Gebo KA, Moore RD, Keruly JC, Chaisson RE. Risk factors for pneumococcal disease in human immunodeficiency virus-infected patients. J. Infect. Dis. 173, 857–862 (1996).
   PubMed Web of Science ®Google Scholar
• Guerrero M, Kruger S, Saitoh A et al. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. AIDS 13, 1971–1975 (1999).
   PubMed Web of Science ®Google Scholar
• Breiman RF, Keller DW, Phelan MA et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch. Intern. Med. 160, 2633–2638 (2000).
   PubMed Web of Science ®Google Scholar
• Navin TR, Rimland D, Lennox JL et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J. Infect. Dis. 181, 158–164 (2000).
   PubMed Web of Science ®Google Scholar
• Bentley DW, Ha K, Mamot K et al. Pneumococcal vaccine in the institutionalized elderly: design of a nonrandomized trial and preliminary results. Rev. Infect. Dis. 3(Suppl.), S71–S81 (1981).
   Google Scholar
• Christenson B, Lundbergh P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 357, 1008–1011 (2001).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Neuzil KM, Yu O et al. Vaccine Safety Datalink. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N. Engl. J. Med. 348, 1747–1755 (2003).
   PubMed Web of Science ®Google Scholar
• Conaty S, Watson L, Dinnes J, Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies comparison with results from randomised controlled trials. Vaccine 22, 3214–3224 (2004).
   PubMed Web of Science ®Google Scholar
• Fine MJ, Smith MA, Carson CA et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch. Intern. Med. 154, 2666–2677 (1994).
   PubMed Web of Science ®Google Scholar
• Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 19, 4780–4790 (2001).
   PubMed Web of Science ®Google Scholar
• Hutchinson BG, Oxman AD, Shannon HS, Lloyd S, Altmayer CA, Thomas K. Clinical effectiveness of pneumococcal vaccine. Meta-analysis. Can. Fam. Physician 45, 2381–2393 (1999).
   PubMed Web of Science ®Google Scholar
• Watson L, Wilson BJ, Waugh N. A systematic review of pneumococcal polysaccharide vaccine in adults. Vaccine 20, 2166–2173 (2002).
   PubMed Web of Science ®Google Scholar
• Moore RA, Wiffen PJ, Lipsky BA. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Fam. Pract. 1, 1 (2000).
   PubMedGoogle Scholar
• Puig Barberà J, Belenguer Barea A, Goterris Pinto M, Brines Benlliure MJ. Effectividad de la vacunación frente al neumococo en el anciano. Revisión sistemática y metaanálisis. Aten Primaria 30, 269–283 (2002).
   PubMedGoogle Scholar
• Klatrersky J, Mommen P, Canteraire F, Safary A. Placebo-controlled pneumococcal immunization in patients with broncogenic carcinoma. Eur. J. Cancer Clin. Oncol. 22, 807–813 (1986).
   PubMedGoogle Scholar
• Schwartz JS. Pneumococcal vaccine: clinical efficacy and effectiveness. Ann. Intern. Med. 96, 208–220 (1982).
   PubMed Web of Science ®Google Scholar
• Musher DM, Groover JE, Rowland JM et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence and response to revaccination. Clin. Infec. Dis. 17, 66–73 (1993).
   PubMed Web of Science ®Google Scholar
• Austrian R, Douglas RM, Schiffman G et al. Prevention of pneumococcal pneumonia by vaccination. Trans. Assoc. Am. Physicians 89, 184–194 (1976).
   PubMedGoogle Scholar
• Willems, Sanders CR, Riddiough MA, Bell JR. Cost–effectiveness of vaccination against pneumococcal pneumonia. N. Engl. J. Med. 303, 553–559 (1980).
   PubMed Web of Science ®Google Scholar
• Office of Technology Assessment, US Congress. A Review of Selected Federal Vaccine and Immunization Policies: Based on Case Studies of Pneumococcical Vaccine. Government Printing Office, WA, USA (1979).
   Google Scholar
• Ammet A, Baltussen R, Duru G et al. Cost–effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries. Clin. Infect. Dis. 31, 444–450 (2000).
   PubMed Web of Science ®Google Scholar
• Levy E. Evaluation socio-économique d’un vaccine contre l’infection pneumococcique. Rev. Epidemiol. Sante Publíque 29, 133–153 (1981).
   PubMed Web of Science ®Google Scholar
• Makela PH, Jokinen C, Pyhala R et al. Use of vaccines for respiratory infections: strategies for influenza and pneumococcal disease. J. Infect. Dis. 70, 141–148 (1990).
   Google Scholar
• Sisk JE, Riegelman RK. Cost–effectiveness vaccination against pneumococcal pneumonia: an update. Ann. Intern. Med. 104, 79–86 (1986).
   PubMed Web of Science ®Google Scholar
• Sisk JE, Moskowitz AJ, Whang W et al. Cost–effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 278, 1333–1339 (1997).
   PubMed Web of Science ®Google Scholar
• Office of Technology Assessment, US Congress. Update of Federal Activities Regarding the Use of Pneumococcical Vaccine: a Technical Memorandum. Government Printing Office, WA, USA (1984).
   Google Scholar
• Gable CB, Holzer SS, Engelhart L. Pneumococcal vaccine efficacy and associated cost savings. JAMA 264, 2910–2915 (1990).
   PubMed Web of Science ®Google Scholar
• Baltussen RMPM, Ament AJHA, Leidl RM, Van Furth R. Cost–effectiveness of vaccination against pneumococcal pneumonia in the Netherlands. Eur. J. Public Health 153–161 (1997).
   Web of Science ®Google Scholar
• De Graeve D, Lombaert G, Goossens H. Cost–effectiveness vaccination in adults and elderly persons in Belgium. Pharmacoeconomics 17, 591–601 (2000).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Heijnen ML, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics 19, 215–222 (2001).
   PubMed Web of Science ®Google Scholar
• Jiménez FJ, Guallar P, Rubio C, Villasante P, Guallar E. Cost–effectiveness analysis of pneumococcal vaccination in the elderly Spanish population. Br. J. Med. Econ. 10, 193–202 (1996).
   Google Scholar
• Whang W, Sisk JE, Heitjan DF, Moskowitz AJ. Probabilistic sensitivity analysis in cost–effectiveness. An application from a study of vaccination against pneumococcal bacteremia in the elderly. Int. J. Technol. Assess. Health Care 15, 563–572 (1999).
   PubMed Web of Science ®Google Scholar
• Postma MJ, Heijnen MA, Beutels P, Jager JC. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands. Expert Rev. Vaccines 2, 477–482 (2003).
   Google Scholar
• Patrick KM, Woolley FRA. Cost–benefit analysis of immunity for pneumococcal pneumonia. JAMA 248, 473–477 (1981).
   Google Scholar
• Laupacis A, Feeny D, Detsky A, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economical evaluations. CMAJ 146, 473–481 (1992).
   PubMed Web of Science ®Google Scholar
• Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am. J. Med. 94, 160–168 (1993).
   PubMed Web of Science ®Google Scholar
• Nichol KL, Baken L, Wuorenma J et al. The health and economics benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch. Intern. Med. 159, 2437–2442 (1999).
   PubMed Web of Science ®Google Scholar
• Vold Pepper P, Owens DK. Cost-effectiveness of pneumococcal vaccine in healthy younger adults. Med. Decis. Making 22(Suppl.), S45–S57 (2002).
   Google Scholar